Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/2 First-in-human Study of the Safety and Efficacy of IMC-C103C as Single Agent and in Combination With Atezolizumab in HLA-A*0201-positive Patients With Advanced MAGE-A4-positive Cancer

NCT03973333 is registered in ClinicalTrials.gov with Immunocore Ltd as lead sponsor.

NCT NCT03973333
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03973333 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/2 First-in-human Study of the Safety and Efficacy of IMC-C103C as Single Agent and in Combination With Atezolizumab in HLA-A*0201-positive Patients With Advanced MAGE-A4-positive Cancer
Lead sponsor
Immunocore Ltd
Phase
Phase 1/2
Overall status
Withdrawn
Start date
May 17, 2019
Completion date
September 25, 2023
Enrollment
0 (actual)
Sites
19

Conditions

As the registry lists them; a condition with its own page is linked.

select advanced solid tumors